Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
713 (USA) · Dr. Kowalski
consented 2014-03-30
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-07-14 (study day 107.0); relationship: PROBABLE
Data queries
No data queries.